NCT00061802View on ClinicalTrials.gov

Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder

PHASE4CompletedINTERVENTIONAL
Enrollment

225

Participants

Timeline

Start Date

June 30, 2003

Study Completion Date

February 29, 2004

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

risperidone, quetiapine

Trial Locations (13)

Unknown

San Diego

Hoffman Est

Lake Charles

Jackson

Visakhapatnam

The Bronx

Oklahoma City

Aurangabad

New Delhi

Orange

San Diego

Lucknow

Richmond

All Listed Sponsors
collaborator

Janssen, LP

INDUSTRY

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00061802 - Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder | Biotech Hunter | Biotech Hunter